1. Home
  2. RYTM vs FRSH Comparison

RYTM vs FRSH Comparison

Compare RYTM & FRSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • FRSH
  • Stock Information
  • Founded
  • RYTM 2008
  • FRSH 2010
  • Country
  • RYTM United States
  • FRSH United States
  • Employees
  • RYTM N/A
  • FRSH N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • FRSH EDP Services
  • Sector
  • RYTM Health Care
  • FRSH Technology
  • Exchange
  • RYTM Nasdaq
  • FRSH Nasdaq
  • Market Cap
  • RYTM 3.8B
  • FRSH 3.9B
  • IPO Year
  • RYTM 2017
  • FRSH 2021
  • Fundamental
  • Price
  • RYTM $61.33
  • FRSH $15.27
  • Analyst Decision
  • RYTM Strong Buy
  • FRSH Buy
  • Analyst Count
  • RYTM 12
  • FRSH 14
  • Target Price
  • RYTM $76.75
  • FRSH $20.00
  • AVG Volume (30 Days)
  • RYTM 632.6K
  • FRSH 2.6M
  • Earning Date
  • RYTM 05-07-2025
  • FRSH 07-29-2025
  • Dividend Yield
  • RYTM N/A
  • FRSH N/A
  • EPS Growth
  • RYTM N/A
  • FRSH N/A
  • EPS
  • RYTM N/A
  • FRSH N/A
  • Revenue
  • RYTM $136,863,000.00
  • FRSH $751,550,000.00
  • Revenue This Year
  • RYTM $37.88
  • FRSH $15.97
  • Revenue Next Year
  • RYTM $72.84
  • FRSH $12.28
  • P/E Ratio
  • RYTM N/A
  • FRSH N/A
  • Revenue Growth
  • RYTM 48.88
  • FRSH 20.46
  • 52 Week Low
  • RYTM $35.35
  • FRSH $10.81
  • 52 Week High
  • RYTM $68.58
  • FRSH $19.77
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 51.78
  • FRSH 57.54
  • Support Level
  • RYTM $58.72
  • FRSH $14.73
  • Resistance Level
  • RYTM $63.24
  • FRSH $16.14
  • Average True Range (ATR)
  • RYTM 2.43
  • FRSH 0.41
  • MACD
  • RYTM -0.15
  • FRSH -0.02
  • Stochastic Oscillator
  • RYTM 65.51
  • FRSH 54.21

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About FRSH Freshworks Inc.

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.

Share on Social Networks: